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Abstract C–C chemokine receptor 1 (CCR1) and CCR5
are involved in various inflammation and immune
responses, and regulate the progression of the autoimmune
diseases differently. However, the number of residues
identified at the binding interface was not sufficient to
clarify the differences in the CCR1- and CCR5-binding
modes to MIP-1a, because the NMR measurement time for
CCR1 and CCR5 samples was limited to 24 h, due to their
low stability. Here we applied a recently developed NMR
spectra reconstruction method, Conservation of experi-
mental data in ANAlysis of FOuRier, to the amide-directed
transferred cross-saturation experiments of chemokine
receptors, CCR1 and CCR5, embedded in lipid bilayers of
the reconstituted high density lipoprotein, and MIP-1a. Our
experiments revealed that the residues on the N-loop and b-
sheets of MIP-1a are close to both CCR1 and CCR5, and
those in the C-terminal helix region are close to CCR5.
These results suggest that the genetic influence of the
single nucleotide polymorphisms of MIP-1a that
accompany substitution of residues in the C-terminal helix
region, E57 and V63, would provide clues toward eluci-
dating how the CCR5–MIP-1a interaction affects the pro-
gress of autoimmune diseases.
Keywords Membrane proteins  G-protein coupled
receptors  Transferred cross-saturation  Nanodiscs 
Sparse sampling  Surface plasmon resonance
Introduction
Chemokine receptors are members of G protein-coupled
receptor (GPCR) superfamily and regulate various
inflammation and immune responses. C–C chemokine
receptor 1 (CCR1) and CCR5 are chemokine receptors
expressed in monocytes, macrophages, and Th1 cells and
recognize C–C type chemokines, such as MIP-1a, MIP-1b,
and RANTES (Devalaraja and Richmond 1999). CCR1 and
CCR5 are therapeutic targets for autoimmune diseases
(O’Hayre et al. 2010; Proudfoot et al. 2010), multiple
sclerosis (MS) and rheumatoid arthritis. CCR1 and CCR5
regulate the progression of these diseases differently
(Mahad et al. 2004), and thus the elucidation of the roles of
CCR1 and CCR5 would provide clues for understanding
the mechanisms underlying the progression of these
autoimmune diseases.
We embedded CCR5 into reconstituted high density
lipoprotein (rHDL), which enabled CCR5 to maintain its
functions for *24 h and thus to be suitable for structural
analyses (Yoshiura et al. 2010). The methyl-directed
transferred cross-saturation (TCS) experiments of the
complex revealed that valine 59 and valine 63 of MIP-1a
are in close proximity to CCR5 in the complex (Yoshiura
et al. 2010; Ueda et al. 2014). However, the number of
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residues identified at the binding interface was not suffi-
cient to clarify the differences in the CCR1- and CCR5-
binding modes to MIP-1a, although a crystal structure of
CCR5 that was engineered to stabilize the inactive state
and bound to an inverse agonist and two crystal structures
of other chemokine–chemokine receptor complexes,
CXCR4–vMIPII and US28–CX3CL1, are available (Tan
et al. 2013; Burg et al. 2015; Qin et al. 2015).
We recently developed an NMR spectra reconstruction
method, ‘‘Conservation of experimental data in ANAlysis
of FOuRier’’ (Co-ANAFOR), to reconstruct the crowded
spectra from the sparsely sampled time-domain data (Ueda
et al. 2015). The number of sampling points required for
the TCS experiments of membrane proteins, photosystem I
and cytochrome b6f, and their ligand, plastocyanin, with
Co-ANAFOR was half of that needed for linear prediction,
and the peak height reduction ratios of the spectra recon-
structed from truncated time-domain data by Co-ANAFOR
were more accurate in our hands than those reconstructed
from non-uniformly sampled data by compressed sensing
(Ueda et al. 2015).
Here, the reconstruction of the truncated time-domain data
by Co-ANAFOR was applied to amide-directed TCS exper-
iments, which enabled the identification of the total binding
interface for analyses of the interactions between chemokine
receptors, CCR1 and CCR5, and their ligand, MIP-1a.
Materials and methods
Preparation of the [ul-2H,15N] MIP-1a variant
The previously prepared MIP-1a variant (P8A/F13Y/
E67Q) expression plasmid (Yoshiura et al. 2010) was
transformed into Escherichia coli strain BL21 Origami B
(DE3) (Novagen). Cells were grown at 37 C in 10 mL of
Luria–Bertani medium for 12 h, and were then harvested
and resuspended in fresh M9 minimal medium. Uniformly
2H- and 15N-labeled proteins for TCS experiments were
produced in 99.8 % 2H2O M9 minimal medium with 1 g/L
15NH4Cl and 2 g/L [
2H7]-glucose. Protein expression was
induced by the addition of isopropyl-b-D-thiogalactopyra-
noside to a final concentration of 0.1 mM when the culture
reached an OD600 of 0.7–0.9. After shaking incubation at
25 C for 20 h, the cells were pelleted by centrifugation at
70009g for 10 min. The MIP-1a variant was prepared as
described previously (Yoshiura et al. 2010).
Preparation of CCR1 and CCR5 with the insect
expression system
The cDNA fragment encoding human CCR1 was amplified
by PCR, and was cloned into the pFastBac1 vector
(Invitrogen). A DNA fragment, encoding with the N-ter-
minal gp64 promoter and gp64 signal sequence and the
C-terminal eight residues of a linker and nine residues
(TETSQVAPA) of bovine rhodopsin was introduced just
before the stop codon of the CCR1 gene, as the 1D4
antibody epitope tag (1D4-tag). This plasmid is referred to
as pFastBac1-CCR1-1D4. Recombinant baculoviruses
were generated using the pFastBac1-CCR1-1D4 plasmid
and the Bac-to-Bac Baculovirus Expression System (In-
vitrogen), according to the manufacturer’s instructions.
Recombinant baculoviruses for CCR5 expression were
prepared as described previously (Yoshiura et al. 2010).
For the large scale expression of CCR1 and CCR5,
express SF? cells (Protein Sciences Corp.) were grown in
1–3 L of Sf900-II serumfree media (Invitrogen) at 27 C,
using 250 mL Erlenmeyer flasks (Corning). When the cells
reached a density of 2.0 9 106 cells/mL, the high titer
virus stock (10 per 100 mL of cells) and 1.25 lg/mL of
E64 (Peptide Institute) were added, and the cells were
harvested 48 h post infection. The cells were lysed by
sonication and subjected to discontinuous sucrose density
gradient ultracentrifugation to purify the membrane frac-
tion, as described previously (Yoshiura et al. 2010).
Preparation of CCR1-rHDL and CCR5-rHDL
The CCR1 or CCR5-containing membrane fraction, pre-
pared from 0.8 L culture of SF? cells, was solubilized with
*10 mL of HBSG buffer (20 mM HEPES, 150 mM NaCl,
20 % glycerol, pH 7.8) containing 1 % DDM and a pro-
tease inhibitor cocktail (Nacalai Tesque). After a 20 min
incubation at 4 C, *8 mg of MSPE3 was added to
achieve a final concentration of *40 lM. The reconstitu-
tion mixture was incubated for 10 min at 4 C, and the
self-assembly process was initiated by adding *1 g of
Bio-Beads SM-2 (Bio-Rad). The mixture was incubated
with the beads for 1 h at 4 C with gentle agitation, and the
beads were then removed. The addition and removal of the
beads were repeated twice.
The reconstitution mixture was mixed with 0.5 mL 1D4-
Sepharose, in which 5 mg/mL of the 1D4 antibody
(University of British Columbia) was coupled to CNBr-
activated Sepharose 4B (GE Healthcare). The mixture was
incubated for 1.5 h at 4 C, and the supernatant was
removed after centrifugation. The beads were washed three
times with 10 mL of HBSG. For the elution of CCR1- or
CCR5-rHDL, the column was incubated for 30 min at 4 C
in the presence of 0.5 mL of HBSG, containing 0.4 mg/mL
of the nonapeptide (TETSQVAPA), and the supernatant
was collected by centrifugation. This elution process was
repeated four times. The eluates were mixed with 1 mL of
Ni-affinity chromatography column resin equilibrated with
the HBSG buffer, and incubated for 2 h at 4 C. The
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column was then washed with 10 mL of HBSG buffer and
10 mL of TCS buffer (20 mM HEPES, 100 mM NaCl,
5 % glycerol, 75 % D2O, pH 6.0). The rHDL was eluted
with 3 mL of TCS buffer containing 100 mM imidazole.
The elution fractions containing CCR1- or CCR5-rHDL
were concentrated to 0.25 mL with an Amicon Ultra 0.5
filter (MWCO 30 K, Millipore), after the removal of the
imidazole.
The yield and purity of the prepared CCR1- or CCR5-
rHDL were analyzed by 15 % SDS-PAGE. Gels were
stained with a Silver Staining Kit (Daiichi Pure
Chemicals).
Guanine nucleotide exchange assay
The heterotrimeric G protein was prepared as described
previously (Yoshiura et al. 2010). The purified CCR1-
rHDL was incubated with the G proteins and the MIP-1a
variant (P8A/F13Y/E67Q), in a final volume of 0.3 mL of
buffer (20 mM HEPES, pH 7.8, 100 mM NaCl, 10 mM
MgCl2, and 10 lM GDP). The reaction mixtures were first
incubated for 1 h at 4 C and subsequently for 30 min at
room temperature with gentle agitation, and then a 30 lL
aliquot of non-hydrolyzable GTP modified with fluorescent
Europium (Eu-GTP, PerkinElmer) was added to a final
concentration of 10 nM. The reaction mixtures were fur-
ther incubated for 30 min at room temperature (*298 K),
and the reaction was terminated by the addition of non-
labeled GTPcS (PerkinElmer) to a final concentration of
5 lM. To capture the Ga subunit with its N-terminal His-
tag, each mixture was combined with 120 lL of the
equilibrated Ni affinity beads, and was diluted with buffer
to a final volume of 0.75 mL. After a 1.5 h incubation, the
beads were applied to three wells in an AcroWell filter
plate (Pall Corporation). To remove the unbound Eu-GTP,
the beads were washed twice by filtration through the filters
with 0.25 mL of the HBSG buffer. The bound Eu-GTP was
measured, using an Envision 2103 Multilabel Reader
(PerkinElmer), with excitation at 320 nm and emission
measured at 620 nm.
SPR analysis
The MIP-1a variant binding activity of CCR1-rHDL was
analyzed using a BIAcore T-100 instrument (GE Health-
care Life Sciences). The 1D4 antibodies were first immo-
bilized on the sensor chip CM5 using standard amine-
coupling chemistry, resulting in a signal of *12,000 res-
onance units. CCR1-rHDL was captured on the sensor chip
via the 1D4 antibodies, at a flow rate of 1 lL/min and at
4 C, resulting in a signal of *3000 resonance units. The
empty-rHDL, composed of MSPE3-1D4 and the lipids
derived from Sf? cells, was captured on the control flow
cell under the same conditions, resulting in a signal of
*3000 resonance units. The flow cells were washed ten
times with injections of 10 lL of running buffer (20 mM
HEPES, pH 7.2, 100 mM NaCl), at a flow rate of 30 lL/
min.
The binding assay was performed in running buffer, at a
flow rate of 30 lL/min and at 25 C, using serial dilutions
of the MIP-1a variant in the 0.13–5.0 lM range. The dis-
sociation constant was obtained from the steady-state curve
fitting analysis, using the Biacore T100 Evaluation Soft-
ware (GE Healthcare Life Sciences).
TCS experiments with MIP-1a, CCR1, and CCR5
The methyl-directed TCS experiments were performed
with 10 lM (final concentration) of [u-2H, (Ile-, Leu-,
Val-13C1H3)] MIP-1a variants and about 1/10 molar
equivalent of CCR1-rHDL, as described previously
(Yoshiura et al. 2010). In the amide-directed TCS experi-
ments, the lyophilized [u-2H, 15N]-MIP-1a variants
(50 lM final concentration) were combined with about
3/50 molar equivalent of CCR1-rHDL or CCR5-rHDL, in
20 mM HEPES, pH 6.0, containing 100 mM NaCl, 75 %
D2O, and 5 % (v/v) glycerol. For negative control experi-
ments, the same experiments were performed with the
sample including the empty-rHDL, composed of the
MSPE3 and lipids derived from Sf? cells. All of the
amide-TCS spectra were recorded at 15 C with a Bruker
Avance 800 spectrometer equipped with a cryogenic probe,
using the pulse scheme described previously (Yoshiura
et al. 2010). The irradiation frequency was set at 1.9 ppm,
and the maximum radio frequency amplitude was 0.21 kHz
for WURST (the adiabatic factor Q0 = 1). The irradiation
time and the additional relaxation time were set to 1 and
4 s, respectively. The maximum evolution times in the 1H
and 15N dimensions before the insertion were 39.9 and
12.3 ms, respectively. The spectra with and without irra-
diation and two spectra with different irradiation times
were recorded for each sample with 512 9 24 complex
points, and 64 scans/FID gave rise to an acquisition time of
*24 h.
The reconstruction by Co-ANAFOR were performed by
in-house developed programs written in a programming
language, Python 2.7, supplemented with extension mod-
ules, Numpy 1.5, Scipy 0.9, and l1l2py (http://slipguru.disi.
unige.it/Software/L1L2Py/). The Tikhonov regularization
factor and the linewidth of the signals in the directly
observed dimension, which were utilized in the recon-
struction by Co-ANAFOR, were set to 0.01 and
±0.02 ppm, respectively. The relaxation rates of the sig-
nals, utilized for the calculation of the inserted data, were
uniformly set to the reciprocal of the maximum evolution
time after the insertion of the calculated data. The
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reconstruction by LP was performed by Topspin 3.1
(Bruker Biospin). The number of coefficients in LP was set
to 8. The square sine with a 90 phase shift window
function was manipulated after the insertion.
Results
Application of Co-ANAFOR to the TCS experiments
with the MIP-1a variant and CCR5-rHDL
Amide-directed TCS experiments of CCR5-rHDL and
MIP-1a were performed with a sample containing *3 lM
non-labeled CCR5 and an excess amount (50 lM) of a
[u-2H, 15N]-labeled MIP-1a variant, which is monomeric
and retains the agonist activity for CCR5 (Yoshiura et al.
2010). Due to the low stability of CCR5, even in the lipid
bilayer environment of rHDL, the NMR measurement time
for this sample was limited to 24 h, and thus over 24
complex data could not be experimentally observed with a
sufficient S/N ratio.
In the spectra from the experimentally recorded data and
the 24-point data inserted for the reconstruction by LP
(Fig. 1a), the resonances from S17 and C51 overlapped
with those from E30 and E57, respectively. In the spectra
without irradiation from the 24-point experimentally
recorded data and the 72-point data inserted for the
reconstruction by LP, the lineshapes, as well as the inten-
sities, of the signals were different from those of the
spectra with irradiation (Fig. 1b). These lineshape differ-
ences would cause errors in the intensity reduction ratios in
the spectra reconstructed by LP. In our previously reported
spectra of the TCS experiments of membrane proteins,
photosystem I and cytochrome b6f, and plastocyanin
reconstructed by LP with sampling coverages identical to
those of Fig. 1b, the lineshapes of the signals with irradi-
ation were also remarkably different from those without
irradiation, and the peak height reduction ratios of the
signals were significantly different from those of the
unreconstructed spectra with 100 % sampling coverage
(Ueda et al. 2015). These results suggest that the peak
height ratios of the spectra in Fig. 1b would be different
from those of the unreconstructed spectra with 100 %
sampling coverage, although the latter are not available,
due to the low stability of CCR5. However, the signal
overlap and distortion were not observed in the spectra
from the experimentally recorded data and the 72-point
data inserted for the reconstruction by Co-ANAFOR
(Fig. 1c).
As in previously reported methyl-directed TCS experi-
ments (Yoshiura et al. 2010), we performed control
experiments, in which rHDL without CCR5 was added to
MIP-1a, to observe the non-specific binding effects, such
as interactions with lipids or the MSPE3 polypeptide. The
difference in reduction ratios (DRRs), which represents the
specific interaction between CCR5-rHDL and the MIP-1a
variant, was calculated for each resonance, by subtracting
the intensity reduction ratio in the control experiment from
that in the TCS experiment. As a result, A10, C11, Y15,
T16, N23, F24, Y28, F29, T31, S32, T44, R46, Q49, V50,
C51, V59, and Q60 exhibited high DRRs ([0.1) (Fig. 2a).
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Fig. 1 Reconstruction of TCS spectra of MIP-1a and CCR5-rHDL.
a–c [1H,15N] TROSY spectra observed at 18.8 T for an excess
amount of [ul-2H, 15N] MIP-1a relative to the CCR5-rHDL, with or
without irradiation. a Spectra from 24-point experimentally observed
data and 24-point data inserted for reconstruction by LP. b, c Spectra
from 24-point experimentally observed data and 72-point data
inserted for reconstruction by LP (b) or Co-ANAFOR (c). For
lineshape clarity, the signals are not labeled in b and c. In a, S17, E30,
C51, and E57, which exhibited signal overlap, have labels enclosed in
boxes. In b, c, resonances with lineshapes in the spectra without
irradiation that are remarkably different from those with irradiation in
(b) are labeled and enclosed in boxes
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These residues are on the N-loop (Y15 and T16), the b-
sheets (A10, C11, N23, F24,Y28, F29, T31, S32, T44, R46,
Q49, V50, and C51), and the C-terminal helix (V59 and
Q60), and form a continuous surface on the b-sheets and
N-loop region around Q49 and the a-helix region around
V59 (Fig. 2b).
TCS experiments with the MIP-1a variant
and CCR1-rHDL
We also performed the TCS experiments with the MIP-1a
variant and CCR1-rHDL. CCR1 was prepared by the
method previously developed for CCR5 (Yoshiura et al.
2010). CCR1, with a C-terminal 1D4 epitope-tag, was
expressed in SF9-insect cells. The plasma membrane of the
Sf9 cells was partially purified by sucrose gradient
ultracentrifugation, to remove the soluble impurities.
CCR1 was solubilized by dodecyl b-D-maltopyranoside
(DDM) and then immediately reconstituted into rHDL,
using MSPE3 with the N-terminal His tag. CCR1 in rHDL
(CCR1-rHDL) was purified by removing the non-recon-
stituted elements, using Ni affinity chromatography, and
then subsequently removing the rHDL without CCR1,
using 1D4 antibody affinity chromatography. The purity of
CCR1-rHDL was[80 %, as judged from the SDS-PAGE
pattern (Fig. 3a). Western-blotting analyses with the 1D4
antibody revealed that about 40 lg (1 nmol) of CCR1
reconstituted in rHDL were obtained from a 1 L Sf9 cul-
ture. The yield was about four times higher than that of
CCR5, and the minor band, which was observed in the
CCR5-rHDL preparation, was still observed but markedly
decreased (Yoshiura et al. 2010), probably because the
higher yield of CCR1 resulted in fewer impurities. In the
electrophoresis analysis (Fig. 3a), the band of CCR1 was
higher than that of CCR5 (Yoshiura et al. 2010), which
may be due to the more basic character of CCR5 (calcu-
lated isoelectric points of CCR1 and CCR5 are 8.8 and
9.45, respectively).
To examine whether CCR1-rHDL retains signal trans-
duction activity, the GDP–GTP exchange assay was per-
formed, using the P8A/F13Y/E67Q variant of MIP-1a,
which exists as a monomer at pH 6.0 and stimulates the
signaling by CCR5 (Yoshiura et al. 2010). The GDP–GTP
exchange process on the Ga subunit was monitored by
measuring the binding of non-hydrolyzable GTP modified
with fluorescent europium. The intensity of the fluores-
cence was increased, dependent on the concentration of the
MIP-1a variant, suggesting that CCR1-rHDL was activated
by the MIP-1a variant and induced the GDP–GTP
exchange on the Ga subunit (Fig. 3b).
We applied SPR to examine the binding between the
MIP-1a variant and CCR1-rHDL. As a result, the respon-
ses were observed upon the addition of the MIP-1a variant
to CCR1-rHDL immobilized on the sensor chip, and the
estimated dissociation constant was *2 lM (Fig. 3c). The
sensorgrams were recorded *12 h after the immobliliza-
tion of CCR1-rHDL, and the maximum response was
comparable to that calculated from the amount of immo-
bilized CCR1-rHDL, suggesting that most of the CCR1-
rHDL retained the ligand binding activity for at least
*12 h.
In the methyl-directed TCS experiments of CCR1-rHDL
and MIP-1a, the resonances from V50 exhibited high
DRRs ([0.1) (Fig. S1 in Online Resource 1). In the amide-
directed TCS experiments along with Co-ANAFOR, C11,
Y15, T16, F24, F29, R46, Q49, and C51 exhibited high
DRRs ([0.07) (Fig. 4a). These residues are on the N-loop
(Y15 and T16) and the b-sheets (C11, F24, F29, R46, Q49,





















Fig. 2 CCR5-binding site on MIP-1a determined with the TCS
method along with Co-ANAFOR. a Plot of the difference in the
reduction ratio (DRR) signal intensities originating from the amide
groups in the amide-directed TCS experiments with MIP-1a and
CCR5-rHDL. Cross-peaks with DRR[ 0.1 and \0.1 are colored
green and gray, respectively. The error bars represent the experi-
mental errors, calculated from the root sum square of (noise level/
signal intensity) in the four spectra, with and without irradiation in the
main and control experiments. Sidechains are denoted in italics.
b Mapping of the affected residues in the TCS experiments with
CCR5-rHDL on the MIP-1a structure (PDB code: 1B53). The
residues with DRR[ 0.1 are colored green. V63, which was
significantly affected in the methyl-directed TCS experiments
(Yoshiura et al. 2010), is colored dark green. The molecular diagrams
were generated with WebLab Viewer Pro (Molecular Simulations,
Inc.)
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Discussion
Although the NMR measurement time for the CCR1 and
CCR5 samples was limited to 24 h due to their low sta-
bility, even in the lipid bilayer environment of rHDL, the
application of Co-ANAFOR to the amide-directed TCS
experiments of MIP-1a with CCR1 and CCR5 revealed
that the residues on the b-sheet and the N-loop region of
MIP-1a around Q49 are in close proximity to CCR1 and
CCR5 (Figs. 2, 4). As described previously (Yoshiura et al.
2010), the interactions observed in the TCS experiments
were those of monomeric MIP-1a, CCR1, and CCR5 that
retain their signal transduction activities, although gly-
cosaminoglycans were absent and the sulfonation state of
the tyrosine residues in CCR1 and CCR5 is unknown. The
binding interfaces are generally consistent with those
Fig. 3 Characterization of CCR1-rHDL. a SDS-PAGE analysis of
CCR1-rHDL. The purified CCR1-rHDL was loaded on a 15 % gel
and silver-stained. b Eu-GTP binding to the complex of CCR1-rHDL
and purified G protein, stimulated by the MIP-1a variant. Eu-GTP
binding was measured after an incubation in the presence of various
concentrations of the MIP-1a variant. Results are expressed as the
percentage over the basal level of binding. Data represent the mean
and SE of triplicate binding determinations from three separate,
representative experiments. c SPR analyses of the interaction between
the MIP-1a variant and CCR1-rHDL. The upper panel represents
overlay plots of the sensorgrams obtained for the interaction between
0.125 and 5 lM of the MIP-1a variant and the immobilized CCR1-
rHDL. The plots based on the steady-state method in SPR are shown
in the lower panel. Each point is the average of 50 data points in the












Fig. 4 CCR1-binding site on MIP-1a determined with the TCS
method along with Co-ANAFOR. a Plot of the difference in the
reduction ratio (DRR) signal intensities originating from the amide
groups in the amide-directed TCS experiments with MIP-1a and
CCR1-rHDL. Cross-peaks with DRR[ 0.07 and \0.07 are colored
green and gray, respectively. The error bars represent the experi-
mental errors, calculated from the root sum square of (noise level/
signal intensity) in the four spectra, with and without irradiation in the
main and control experiments. Sidechains are denoted in italics.
b Mapping of the affected residues in the TCS experiments with
CCR1-rHDL on the MIP-1a structure (PDB code: 1B53). The
residues with DRR[ 0.07 are colored magenta. V50, which was
significantly affected in the methyl-directed TCS experiments (see
Fig. S1 in Online Resource), is colored dark purple. These molecular
diagrams were generated with WebLab Viewer Pro (Molecular
Simulations, Inc.)
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identified in the previously reported mutational studies on
MIP-1a (Laurence et al. 2000, 2001; Bondue et al. 2002;
Proudfoot et al. 2003), which shares 68 % sequence iden-
tity with MIP-1a, and the two-step binding mode proposed
in our previous NMR studies (Kofuku et al. 2009) (See text
in the Online Resource 1 for details).
The distinct expression patterns of CCR1 and CCR5,
which were previously observed in the pattern II and pat-
tern III MSs, suggested that CCR1 and CCR5 play different
roles in inflammation (Mahad et al. 2004). Therefore,
genetic analyses of CCR1 and CCR5 would provide clues
toward elucidating how CCR1 and CCR5 affect the pro-
gress of MS and other autoimmune diseases. In addition,
both CCR1 and CCR5 bind to several C–C type
chemokines, such as MIP-1a, MIP-1b, and RANTES, and
thus genetic analyses of each chemokine–chemokine
receptor interaction are also important. A comparison of
the CCR1- and CCR5-binding sites on MIP-1a revealed
that the residues in the a-helix region around V59 are only
involved in the CCR5-binding site (Fig. 5). This region
includes E57 and V63, which are substituted in several
reported single nucleotide polymorphisms (SNPs) with
non-synonymous amino acids (Modi et al. 2006; Yoshiura
et al. 2010). Therefore, these SNPs would specifically
affect the CCR5–MIP-1a interaction, and the genetic
influence of these SNPs in MS or other autoimmune dis-
eases would provide clues toward elucidating how the
CCR5–MIP-1a interaction affects the progress of autoim-
mune diseases (Mahad et al. 2004).
Although there are 28 C–C chemokines that share a
similar fold, only nine and seven C–C chemokines,
including MIP-1a, reportedly bind to CCR1 and CCR5,
respectively (Allen et al. 2007). This ligand selectivity of
chemokines plays important roles in the complex regula-
tion of immune responses (Devalaraja and Richmond 1999;
Mantovani 1999; Allen et al. 2007). Whereas most of the
residues on the binding interfaces are highly conserved
between the chemokines, three residues in the center of the
binding site, A10, F29, and Q49, are not conserved except
for MIP-1a and RANTES, which reportedly bind to both
CCR1 and CCR5 (Fig. S2 in Online Resource 1). There-
fore, the binding specificity would be at least partly due to
the conservation of these residues.
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